Kanada - anglų - Health Canada

jamp pharma corporation - lisinopril (lisinopril dihydrate) - tablet - 5mg - lisinopril (lisinopril dihydrate) 5mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

jamp pharma corporation - lisinopril (lisinopril dihydrate) - tablet - 10mg - lisinopril (lisinopril dihydrate) 10mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

jamp pharma corporation - lisinopril (lisinopril dihydrate) - tablet - 20mg - lisinopril (lisinopril dihydrate) 20mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

mylan pharmaceuticals ulc - lisinopril (lisinopril dihydrate) - tablet - 5mg - lisinopril (lisinopril dihydrate) 5mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

mylan pharmaceuticals ulc - lisinopril (lisinopril dihydrate) - tablet - 10mg - lisinopril (lisinopril dihydrate) 10mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

mylan pharmaceuticals ulc - lisinopril (lisinopril dihydrate) - tablet - 20mg - lisinopril (lisinopril dihydrate) 20mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

auro pharma inc - lisinopril (lisinopril dihydrate) - tablet - 5mg - lisinopril (lisinopril dihydrate) 5mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

auro pharma inc - lisinopril (lisinopril dihydrate) - tablet - 10mg - lisinopril (lisinopril dihydrate) 10mg - angiotensin-converting enzyme inhibitors

Kanada - anglų - Health Canada

auro pharma inc - lisinopril (lisinopril dihydrate) - tablet - 20mg - lisinopril (lisinopril dihydrate) 20mg - angiotensin-converting enzyme inhibitors

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

a-s medication solutions - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 5 mg - lisinopril tablets, usp are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a var